AIMS/HYPOTHESIS: Soluble CD163 (sCD163) was recently identified as a strong risk marker for developing type 2 diabetes. We hypothesised that sCD163 independently associates with insulin resistance. METHODS: This cross-sectional study includes 234 participants: 96 with type 2 diabetes, 34 with impaired glucose tolerance (IGT) and 104 with normal glucose tolerance (NGT), matched for sex and BMI. Glucose-lowering medication was paused for 1 week before plasma samples were obtained for determination of sCD163 and other inflammatory and metabolic variables. Insulin resistance was estimated by homeostasis model assessment of insulin resistance (HOMA-IR). RESULTS: Concentrations of sCD163 were 1.95 mg/l (0.63-6.97) in individuals with type 2 diabetes, 1.64 mg/l (0.58-4.19) in those with IGT, and 1.48 mg/l (0.48-4.11) (median [range]) in those with NGT (p < 0.0001). In univariate analyses, sCD163 correlated significantly with HOMA-IR (R = 0.44), insulin (R = 0.41), glucose (R = 0.30), triacylglycerol (R = 0.29) and HDL-cholesterol (R = -0.34) (all p < 0.0001). All but glucose remained significant when adjusting for age, sex, BMI and glycaemic group. In univariate regression analyses, HOMA-IR was associated with sCD163, C-reactive protein (CRP), TNF-α and IL-6 (all p ≤ 0.0001). An increase of 50% in sCD163 resulted in an estimated increase in HOMA-IR of 36% (95% CI 26, 48; p < 0.0001). In multiple linear regression analyses, sCD163 (p = 0.001) and CRP (p = 0.01) remained independent predictors of HOMA-IR, whereas TNF-α and IL-6 did not. CONCLUSIONS/ INTERPRETATION: Macrophage-specific sCD163 was strongly associated with insulin resistance independently of TNF-α and other predictors. Moreover, sCD163 was associated with well-known variables of the metabolic syndrome.
AIMS/HYPOTHESIS: Soluble CD163 (sCD163) was recently identified as a strong risk marker for developing type 2 diabetes. We hypothesised that sCD163 independently associates with insulin resistance. METHODS: This cross-sectional study includes 234 participants: 96 with type 2 diabetes, 34 with impaired glucose tolerance (IGT) and 104 with normal glucose tolerance (NGT), matched for sex and BMI. Glucose-lowering medication was paused for 1 week before plasma samples were obtained for determination of sCD163 and other inflammatory and metabolic variables. Insulin resistance was estimated by homeostasis model assessment of insulin resistance (HOMA-IR). RESULTS: Concentrations of sCD163 were 1.95 mg/l (0.63-6.97) in individuals with type 2 diabetes, 1.64 mg/l (0.58-4.19) in those with IGT, and 1.48 mg/l (0.48-4.11) (median [range]) in those with NGT (p < 0.0001). In univariate analyses, sCD163 correlated significantly with HOMA-IR (R = 0.44), insulin (R = 0.41), glucose (R = 0.30), triacylglycerol (R = 0.29) and HDL-cholesterol (R = -0.34) (all p < 0.0001). All but glucose remained significant when adjusting for age, sex, BMI and glycaemic group. In univariate regression analyses, HOMA-IR was associated with sCD163, C-reactive protein (CRP), TNF-α and IL-6 (all p ≤ 0.0001). An increase of 50% in sCD163 resulted in an estimated increase in HOMA-IR of 36% (95% CI 26, 48; p < 0.0001). In multiple linear regression analyses, sCD163 (p = 0.001) and CRP (p = 0.01) remained independent predictors of HOMA-IR, whereas TNF-α and IL-6 did not. CONCLUSIONS/ INTERPRETATION: Macrophage-specific sCD163 was strongly associated with insulin resistance independently of TNF-α and other predictors. Moreover, sCD163 was associated with well-known variables of the metabolic syndrome.
Authors: Jing Chen; Rachel P Wildman; L Lee Hamm; Paul Muntner; Kristi Reynolds; Paul K Whelton; Jiang He Journal: Diabetes Care Date: 2004-12 Impact factor: 19.112
Authors: Jonas Axelsson; Holger Jon Møller; Anna Witasp; Abdul Rashid Qureshi; Juan Jesus Carrero; Olof Heimbürger; Peter Bárány; Anders Alvestrand; Bengt Lindholm; Søren K Moestrup; Peter Stenvinkel Journal: Am J Kidney Dis Date: 2006-12 Impact factor: 8.860
Authors: M Zeyda; D Farmer; J Todoric; O Aszmann; M Speiser; G Györi; G J Zlabinger; T M Stulnig Journal: Int J Obes (Lond) Date: 2007-06-26 Impact factor: 5.095
Authors: Andrew P Levy; K Raman Purushothaman; Nina S Levy; Meerarani Purushothaman; Merav Strauss; Rabea Asleh; Stuart Marsh; Osher Cohen; Soren K Moestrup; Holger J Moller; Elias A Zias; Daniel Benhayon; Valentin Fuster; Pedro R Moreno Journal: Circ Res Date: 2007-05-24 Impact factor: 17.367
Authors: Michael Reid; Yifei Ma; Rebecca Scherzer; Jennifer C Price; Audrey L French; Michael W Plankey; Carl Grunfeld; Phyllis C Tien Journal: AIDS Date: 2017-01-28 Impact factor: 4.177
Authors: Christina Brock; Birgitte Brock; Anne Grave Pedersen; Asbjørn Mohr Drewes; Niels Jessen; Adam D Farmer Journal: World J Diabetes Date: 2016-08-25
Authors: Pia Deichgræber; Daniel R Witte; Holger J Møller; Mette V Skriver; Bjørn Richelsen; Marit E Jørgensen; Nanna B Johansen; Annelli Sandbæk Journal: Diabetologia Date: 2016-08-19 Impact factor: 10.122
Authors: Zhila Semnani-Azad; Philip W Connelly; Luke W Johnston; Ravi Retnakaran; Stewart B Harris; Bernard Zinman; Anthony J Hanley Journal: J Clin Endocrinol Metab Date: 2020-03-01 Impact factor: 5.958